The s5/s5i/CORE/CORE Mobile Precision Guided Therapy System from Volcano Corporation is an ultrasonic pulsed echo imaging system used in the diagnosis and treatment of cardiac disease. The system complies with the U.S. Food and Drug Administration (FDA) regulation 21 CFR 892.1560, which applies to ultrasonic pulsed echo imaging systems.
This document is an FDA 510(k) premarket notification clearance letter and summary for the Volcano s5/s5i/CORE/CORE Mobile Precision Guided Therapy System. The letter lists the trade/device name, regulation number 21 CFR 892.1560, regulatory Class II, product code IYO, and states that the device was found substantially equivalent to legally marketed predicate devices.
The 510(k) summary, dated December 19, 2017, identifies Volcano Corporation as submitter and describes the device as a mobile imaging and pressure management system. It lists indications for use covering qualitative and quantitative evaluation of vascular morphology in coronary and peripheral vasculature, use as an adjunct to conventional angiographic procedures, ChromaFlo, VH IVUS, pressure measurement, rotational 45 MHz, Pullback, FFR v2.5, and iFR modalities.
| Pullback distance | Maximum of 15 cm |
|---|---|
| iFR diagnostic cut-point | 0.89 |
The document describes it as a mobile imaging and pressure management system.
It is 0.89, which the document says represents an ischemic threshold.
The imaging core is withdrawn within the protective sheath for a maximum of 15 cm.
The device is listed as Class II with product code IYO under 21 CFR 892.1560.